Core Viewpoint - Esperion has entered into privately negotiated exchange and subscription agreements to issue $100 million of new convertible senior subordinated notes, replacing existing notes due in 2025 with new notes due in 2030 [1][2]. Group 1: Exchange and Subscription Transactions - The company will issue approximately $57.5 million in new notes and $153.4 million in cash in exchange for approximately $210.1 million of existing 2025 notes, along with an additional $42.5 million in new notes for cash [1][3]. - The transactions are expected to close on or about December 17, 2024, subject to customary closing conditions [2]. Group 2: Financial Details and Use of Proceeds - Esperion will not receive cash proceeds from the exchange transactions but expects to receive approximately $42.5 million from the subscription transactions, which will be used for general corporate purposes [3]. - The new notes will have a semi-annual interest rate of 5.75% and will mature on June 15, 2030, with an initial conversion rate of 326.7974 shares per $1,000 principal amount [4]. Group 3: Redemption and Repurchase Rights - The new notes can be redeemed by the company starting December 20, 2027, under certain conditions, with the redemption price equaling the principal amount plus accrued interest [5]. - In the event of a fundamental change, holders may require the company to repurchase their notes at the principal amount plus accrued interest [6]. Group 4: Regulatory and Placement Information - The new notes will be issued only to accredited institutional investors and have not been registered under the Securities Act [7]. - The exchange transactions will be partially funded by a new $150 million senior secured term loan credit facility with Athyrium Capital Management [8].

Esperion Therapeutics, Inc. (ESPR) announced that it has filed new drug submissions (NDSs) in Canada to seek approval for its once-daily, oral non-statin drugs Nexletol (bempedoic acid) and Nexlizet as a treatment to reduce low-density lipoprotein cholesterol or LDL-C (bad cholesterol) and cardiovascular risk.Nexlizet is a combination of bempedoic acid and ezetimibe.Shares of the company were up 10.7% on Dec. 2 following the announcement of the news.ESPR stock has increased 3.6% so far this year against the ...

Group 1 - The core viewpoint is that Esperion Therapeutics, Inc. (NASDAQ: ESPR) maintains a buy rating due to its strong Q3 2024 financial performance, highlighting the effectiveness of its unique value proposition [1] Group 2 - The company has demonstrated a successful financial analysis track record across diverse industries, showcasing expertise in evaluating investment opportunities and assessing risk profiles [1] - The financial modeling and data analysis capabilities are emphasized, indicating a focus on providing accurate insights and recommendations for informed financial decisions [1]

Esperion Therapeutics, Inc. (ESPR) incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred a loss of 37 cents per share in the year-ago quarter.Esperion generated revenues of $51.6 million, up nearly 52% year over year, driven by higher collaboration revenues and product revenues in the United States. However, the reported figure missed the Zacks Consensus Estimate of $55 million.Shares of Esperion ...

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.14%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.15 per share when it actually produced a loss of $0.05, delivering a surprise of 66.67%.Over the last four quarters, ...

– Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – – Total Retail Prescription Equivalents Increased 12% and New to Brand Prescriptions Grew 18% from Second Quarter – – October 2024 Total Retail Prescription Equivalents Increased 17% and New to Brand Prescriptions Grew 20% Compared to First Four Weeks of Q3 2024 – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Esper ...

ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 11:30 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Es ...

ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN. A live audio webcast can be accessed on the investor and media sec ...

Company Overview - Esperion is focused on discovering, developing, and commercializing innovative medicines aimed at improving outcomes for patients with cardiovascular and cardiometabolic diseases [4] - The company addresses the unmet health needs of millions suffering from high cholesterol, emphasizing the importance of reducing LDL-cholesterol levels effectively [4] Equity Incentive Plan - On September 23, 2024, Esperion granted 3,500 restricted stock units (RSUs) to a new employee under its 2017 Inducement Equity Incentive Plan [1] - The 2017 Inducement Equity Incentive Plan is designed for granting equity awards to individuals who are new hires or returning after a bona fide period of non-employment, as an inducement for joining the company [2] RSU Vesting Schedule - Each RSU will vest 25% on the one-year anniversary of the vesting commencement date, with the remaining 75% vesting in twelve equal quarterly installments thereafter, contingent on the employee's continued employment [3]

It has been about a month since the last earnings report for Esperion Therapeutics (ESPR) . Shares have lost about 3.9% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Esperion Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Esperion's Q2 Loss Narrow ...